Stay up to date with the latest news and activities at AKESOgen.

RenalytixAI Logo

RenalytixAI and AKESOgen In Joint Venture Partnership for Expanded Testing Capacity and Pharma Services

NEW YORK, Feb. 13, 2019 — RenalytixAI (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of clinical trial precision medicine services located in Atlanta, Georgia.

AKESOgen brings a state-of-the-art 14,000 square foot CLIA1 certified and CAP2 accredited laboratory facility that enables RenalytixAI to immediately scale operations to support additional business partnerships on a variable-cost basis without incurring additional fixed overhead. RENX AI Labs provides RenalytixAI with further operations outside of its recently configured New York City-based clinical laboratory operations in JLABS, a Johnson & Johnson Innovation center.

The joint venture, named RENX AI Labs, LLC, significantly expands the operational capacity available to RenalytixAI. RENX AI Labs will provide services directly to health systems and pharmaceutical companies located in all regions of the United States. The joint venture enables RenalytixAI to support prospective revenue-generating contract research, clinical diagnostic and clinical trial services that are part of the Company’s core business model with KidneyIntelXTM and other products under development.

RENX AI Labs will help support the programs of pharmaceutical companies by applying AI-enabled diagnostics, beginning with KidneyIntelX, which is currently undergoing clinical validation, to improve patient characterization3 and enrich targeting of patients for drug clinical trials for renal disease. Better identification and characterization of enrolled patients has the potential to reduce trial cost and duration, and increases the likelihood of reaching successful outcomes. RENX AI Labs also has the capability to develop companion diagnostics under stringent quality-control processes.

About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant and an estimated $114 billion is spent annually treating chronic kidney disease in the US.

About AKESOgen
AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, AKESOgen’s services include providing high-throughput, biomarker profiling, microarray, sequencing, genomics, microbiome and epigenomics analysis utilizing different types of markers. For more information, visit www.akesogen.com.

About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

Notes:
1 The Centers for Medicare & Medicaid Services (CMS) regulates all laboratory testing (except research) performed on humans in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA). In total, CLIA covers approximately 260,000 laboratory entities. The Division of Clinical Laboratory Improvement & Quality, within the Quality, Safety & Oversight Group, under the Center for Clinical Standards and Quality (CCSQ) has the responsibility for implementing the CLIA Program. https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html?redirect=/clia/

2 The College of American Pathologists (CAP’s) Laboratory Accreditation Program accredits the entire spectrum of laboratory test disciplines with the most scientifically rigorous customized checklist requirements. https://www.cap.org/laboratory-improvement/accreditation

3 Characterization refers to an individual patient’s disease status and underlying biology. Kidney disease biology and status may vary from patient to patient and could have a material impact on whether or not a patient qualifies for a particular drug enrollment criteria.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen, Inc. Selected as a 2018 Atlanta Metro Export Challenge Winner

orbatl_icon

AKESOgen, Inc. Selected as a 2018 Atlanta Metro Export Challenge Winner

AKESOgen, Inc. Receives $5,000 Grant to Grow Internationally

ATLANTA – November 6th, 2018 AKESOgen, Inc. is a recipient of a $5,000 grant in the annual Atlanta Metro Export Challenge (Atlanta MEC), a grant program designed to engage small- and medium-sized businesses in metro Atlanta in the development of international sales plans.

Companies from all over the 29-county region, ranging in size from pre-revenue startups to small and established medium-sized businesses, applied to the program. Thirty companies were selected in the competition and will each receive a grant of $5,000 to apply towards the growth of their international business.

“AKESOgen is honored to be a winner of the Atlanta Metro Export Challenge. This grant will help AKESOgen expand its services internationally as a global forward thinking company.”

AKESOgen offers a wide array of genomic services that include next generation sequencing, microarray processing, DNA and RNA extractions for a variety of industries such as consumer genomics, biotech, pharma, academia, and forensics.

To see the full list of grant awardees, click here

The Atlanta MEC is one of many ways to engage small- and medium-sized companies in metro Atlanta in the development of their international business. Over the last two years, the program has given out more than $400,000 to metro Atlanta companies thanks to the generous sponsorship of JPMorgan Chase & Co, which again contributed $100,000 to this year’s program. Additional sponsorship came from the Metro Atlanta Chamber, UPS, Johnson Controls and Partnership Gwinnett.

“JPMorgan Chase is pleased to help metro Atlanta businesses grow in the international economy,” said David Balos, head of JPMorgan Chase’s Middle Market Banking group in Georgia. ‘’These grants will help companies spend time in their target markets to meet with distributors, partners, and potential customers. Seeing metro Atlanta companies grow their international business will consequently lead to job creation and growth of the metro Atlanta economy.”

The Atlanta MEC is being implemented by ORBATL, a regional partnership of metro Atlanta public and private leaders that enables businesses to grow in the global economy through trade and foreign direct investment.

About AKESOgen
AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

###

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen, Genetic Direction partner on Nutrisystem’s launch of Groundbreaking DNA Body Blueprint™ Nationwide

All New DNA Body Blueprint Provides Integrated Personal Action Plan Focusing on Genetic-Based Eating Behaviors, Nutrition and Metabolism

Simple, Effective and Secure At-Home DNA Test is Supported by Science and Comprehensively Developed to Help Weight Loss and Weight Management

Nutrisystem DNA Body Blueprint Logo

FORT WASHINGTON, Pa.-Nutrisystem, Inc. (Nasdaq: NTRI), a leading provider of health and wellness and weight management products and services including Nutrisystem® and South Beach Diet® brands, today announced the launch of DNA Body Blueprint™, a genetic-based product using a proprietary algorithm that provides an integrated personal action plan focused on eating behaviors, nutrition and metabolism. The national marketing campaign will debut this week.

“By providing a personalized overview that is the ultimate roadmap for an individual’s ongoing nutritional needs, this product delivers on our mission of helping consumers make more informed choices and achieve outcomes that drive overall health,” commented Dawn Zier, President and CEO, Nutrisystem, Inc. “This groundbreaking use of DNA technology is a major step forward in the areas of weight loss, maintenance, and personalized nutrition. Consumer interest is high and we believe this product will attract new consumers to our brand as well as allow us to extend our relationship with them as they transition from weight loss to an ongoing healthy lifestyle.”

Years of Development Leads to National Debut

As a leader with a history in innovative and scientifically-backed weight loss solutions, Nutrisystem greenlighted the creation of DNA Body Blueprint based on a thorough assessment of market dynamics and scientific reviews from its Science Advisory Board. The board consists of a team of renowned professionals, each with distinct backgrounds and expertise, who helped evaluate existing research to enhance current programs, as well as develop new programs utilizing the latest science and technology trends within weight management.

Nutrisystem DNA Body Blueprint
The Company worked closely with and entered into an exclusive agreement with Genetic Direction, a leading provider of DNA-based health management programs, to develop a simple and secure DNA test that uses advanced genetic testing technology and genomic analysis to create an innovative and comprehensive product in the weight loss and weight management space. Proprietary algorithms were designed to accurately analyze genetic variants known as single nucleotide polymorphisms (SNPs) that may affect absorption and uptake of nutrients, processing of nutrients, metabolism, behaviors and optimal fitness approaches. For example, customers will discover whether they are more genetically inclined to lose weight and maintain weight loss, whether they have a slower or faster metabolism, and how their body processes macronutrients such as carbohydrates, fats and proteins, and what to do about it. Customers will be able to discuss their personalized report with a weight loss counselor and tailor their program based on the report findings.

“Nutrisystem, along with our Science Advisory Board, has had an eye on this space over the last few years and is pleased to see the technology safely and constructively evolve,” said David Burton, Executive Vice President of Operations at Nutrisystem, Inc. “Our mission is to match the most cutting-edge scientific developments with proven nutritional data to give our customers the best weight management experience possible, and we’re pleased to bring this to market after having worked extensively on this initiative for the last 24 months. We did an exhaustive search for the right partners and are proud to be rolling out a high-caliber offering at scale with unprecedented personalization.”

Dr. Tim Church, Medical Director, Genetic Direction, a distinguished researcher and specialist in public health and general preventive medicine and one of the country’s leading physicians in exercise and obesity research, echoed this sentiment, saying, “We’ve worked for many years to refine the science behind DNA testing as it relates to health and wellness. We now have a product that can make a difference in peoples’ lives and by working with Nutrisystem, together we can raise broad awareness and prompt mainstream adoption.”

Nutrisystem, through Genetic Direction, will be utilizing AKESOgen, an industry leading global genetic testing lab, to provide data and results using the most secure data encryption technology available, including de-identified samples and barcode matching.

Dr. Mark Bouzyk, Chief Scientific Officer, AKESOgen, who has been a global scientific leader in the precision genetics space over the last two decades commented, “The time is right to leverage the most robust and exciting scientific discoveries over the last several years in the public health and wellness continuum to benefit the community at large. This comes at a time of unprecedented cost benefits in genetic technologies that is coincidentally timely for the consumer market. Coupling this with Nutrisystem’s vision is absolutely a win-win for all.”

National Advertising & Marketing Campaign

DNA Body Blueprint is slated to be prominently featured in national multi-media marketing and advertising campaigns debuting today, July 16.

“We are thrilled to introduce our DNA-informed product nationwide, via television, social, paid digital, and eCRM. Our DNA Body Blueprint leverages what Nutrisystem does better than anyone. We start with cutting edge science, then make it simple and easy to understand. We’re excited to provide each customer with a blueprint to lose weight successfully. It’s the healthy eating approach designed by your body,” explained Keira Krausz, CMO, Nutrisystem, Inc. “We worked closely with potential customers to develop both the product and our campaign, and we know their ongoing insights will play a pivotal role in how we continue to evolve the offering.”

View one of the Body Blueprint DNA national television ads here.

White Paper & Fact Sheet

The Science Behind Nutrisystem® DNA Body Blueprint™ White Paper can be found here.
Authors: LeeAnn Kindness, MS, Mandi Knowles, RDN/LDN, Courtney McCormick, MPH, RDN/LDN, Noah Voreades, MS, Mark Bouzyk, PhD, Dr. Mark Sarzynski
Reviewers: Gary Bennett, PhD., Ted Kyle, RPh, MBA

Additional information on the Nutrisystem DNA Body Blueprint can be found here along with a fact sheet, here.

About Nutrisystem, Inc.

Nutrisystem, Inc. (Nasdaq: NTRI) is a leader in the weight-loss industry, having helped millions of people lose weight over the course of more than 45 years. The Company’s multi-brand approach to weight loss includes multiple plans for 2018. For more information, go to NutrisystemNews.com and Newsroom.SouthBeachDiet.com.

About Genetic Direction

Genetic Direction is a healthcare software company that improves individuals’ lives by evaluating key genetic markers and developing personalized health management programs in the areas of weight management, healthy aging and peak athletic performance. Genetic Direction’s proprietary algorithms and protocols utilize the latest peer-reviewed genetic research and are delivered to consumers, clients and patients through healthcare providers, retail marketing partners and directly via its secure web platform and one-on-one telehealth consultations.

About AKESOgen

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

Contacts

Nutrisystem, Inc.
Robin McConnell Shallow
Senior Vice President, Corporate Communications and Public Relations
215-346-8068
rshallow@nutrisystem.com
or
ICR, Inc.
John Mills, Partner
646-277-1254
ir@nutrisystem.com
John.Mills@Icrinc.com

AKESOgen, Inc.
Mark Bouzyk, Ph.D.
Chief Scientific Officer
770 542 0890
mbouzyk@akesogen.com
www.akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Disease Risk to Include Saliva Samples

Cytox Ltd

 

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Disease Risk to Include Saliva Samples


Pioneering polygenic risk scoring approach verified for banked DNA, blood and saliva samples

 

8th May 2018: Oxford & Manchester, UK and Atlanta, GA.  Cytox, a precision medicine testing company which today is commercializing polygenic risk scoring (PRS) and other approaches for assessing genetic risk for developing Alzheimer’s disease, has collaborated with integrated genomics and genetics leader AKESOgen to verify the performance of the Cytox genoBAR™ test with saliva samples.

 

The Cytox genoBAR research test is intended to help pharma, biotech, and sponsors of large cohort studies reduce the time and high cost associated with identifying and stratifying subjects for clinical trials and large-population research, which can take more than six months and run tens of thousands of dollars per participant. The work performed by Cytox and AKESOgen resulted in over 99% concordance between the SNPs used in the PRS identified from blood and saliva samples collected from the same subjects and run on the Cytox variaTECT™ microarray on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform from Thermo Fisher Scientific. The saliva samples were collected using the DNA Genotek DNA saliva collection kit. The results of this verification study will provide an additional means to collect DNA from prospective clinical trial and cohort subjects and opens the possibility of screening even larger population groups for disease risk.

 

“The extension of our test to include saliva samples in addition to blood samples and biobanked DNA represents a significant step forward,” commented Dr Richard Pither, CEO of Cytox, “Our customers in pharma and biotech now have the ability to collect larger numbers of samples in a highly efficient and non-invasive way, opening the doors to the cost-effective screening of tens to hundreds of thousands of prospective clinical study participants, or still larger population networks associated with regional healthcare centres or national dementia programmes.”

 

Dr Mark Bouzyk, Chief Scientific Officer at AKESOgen, added, “The collaboration between AKESOgen and Cytox aims to ensure the highest accuracy possible across all the biological samples types generally used for genetic analysis. We believe these results and our partnership with Cytox will eventually result in more effective screening and diagnosis for those patients impacted by Alzheimer’s disease.”

 

-ends-

 

About Cytox

Cytox Group Limited is a precision medicine information company whose mission is to transform how treatments are developed, people are screened and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s disease. Alzheimer’s disease today impacts over 46 million people globally, reaching 74.7 million in 2030 and projected to grow to over 131 million people by 2050 with an economic impact to exceed two trillion dollars. Leveraging the proprietary Cytox variaTECT™ SNP genotyping array, Cytox SNPfitR™ algorithm for polygenic risk scoring and running on the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform, the company offers genomic profiling testing assays and services to early access collaborators in academia and Biopharma pursuing clinical research and drug development. The service is designed to help researchers and clinicians access the biology and genetics behind dementia, stratify patients to enable more cost effective and information rich clinical trials, and ultimately establish risk for cognitive decline and matching with the most appropriate targeted therapy.

 

The company is headquartered in the United Kingdom with assays and services available to early access collaborators globally. For more information, please visit www.cytoxgroup.com and follow the company on Twitter at @CytoxDx and on LinkedIn. Cytox’s assay and testing services are for research use only and not for use in diagnostic procedures.

 

About AKESOgen

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

 

 

Contact:

Cytox Limited

Richard Pither, CEO

+44(0) 1865 338018

richard.pither@cytoxgroup.com

www.cytoxgroup.com

 

AKESOgen

Mark Bouzyk, CSO

+1 770 542 0890

mbouzyk@akesogen.com

www.akesogen.com

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen recognized as Georgia Small Business Rock Star of 2018

Georgia Economic Development Association

 

AKESOgen recognized as Georgia Small Business Rock Star

 

ATLANTA – March 19, 2018—AKESOgen was recognized by the state of Georgia as a Small Business Rock Star today at a luncheon hosted by the Georgia Department of Economic Development (GDEcD) and the Georgia Economic Developers Association (GEDA).

 

“What an honor it is to celebrate Georgia’s Small Business Rock Stars during the state’s annual Small Business Week,” said Commissioner Pat Wilson. “Anytime that we can put a spotlight on Georgia’s small businesses is a win-win for the state. These companies keep our economy thriving, and help Georgia maintain its status as the No.1 state in the nation in which to do business.”

 

Genetics and understanding your own genetic make up (DNA) is becoming pervasive in society. i.e. what makes you who you are. We are applying these new genetic technologies in fields such as cancer and Alzheimer’s as well as consumer genomics.” said Dr. Mark Bouzyk, Chief Scientific Officer at AKESOgen. “We are offering new precision medicine testing to understand outcomes and help identify which medicines make sense for the patient. In order for us to have grown this critical business we are deeply indebted to the outstanding support of GDEcD, Partnership Gwinnett, Georgia’s Innovation Crescent, the Georgia Research Alliance and GeorgiaBIO”.

 

This year’s Small Business Rock Stars winners include: AKESOgen, Inc. from Gwinnett County; STRAND Clinical Technologies from Columbia County; Gottwals Books from Peach County and SouthLife Supply Co. from Thomas County.

 

“With almost 98 percent of Georgia companies employing fewer than 100 people, small business has a tremendous impact on Georgia’s economy,” said GDEcD Director of Entrepreneur & Small Business Mary Ellen McClanahan. “The Rock Star recognition provides the perfect opportunity to showcase how important small businesses are to the state and of course, the local economy.”

 

These companies have shown increases in revenue, sales, exporting, product lines, jobs and economic impact. Additionally, the Small Business Rock Stars have shown dedication to their entrepreneurial spirit, creativity and a unique approach to conducting business to take them to the next level.

 

Governor Nathan Deal declared March 19-23 as Georgia Small Business Week to celebrate the achievements made my small businesses throughout the state.

 

“GEDA supports all types of economic development where jobs and investment are created, and where the quality of life is improved for our citizens,” said GEDA President Kevin Shea. “We are proud to support small businesses of all sizes through our members and their organizations all over the State of Georgia. Congratulations to this year’s award-winning small businesses.”

 

 

The Georgia Department of Economic Development’s small business efforts and outreach are directed by GDEcD Director of Entrepreneur & Small Business Mary Ellen McClanahan.  To access more information about these programs and more visit www.georgia.org/rockstars and www.georgia.org/smallbusinessweek.

 

###

 

About the Georgia Department of Economic Development

The Georgia Department of Economic Development (GDEcD) plans, manages and mobilizes state resources to attract new business investment to Georgia, drive the expansion of existing industry and small business, locate new markets for Georgia products, inspire tourists to visit Georgia and promote the state as a top destination for arts events and film, music and digital entertainment projects.

 

About GEDA

Celebrating 51 years of service excellence, the Georgia Economic Developers Association is the leading professional organization advancing Georgia’s economic vitality. GEDA is a non-profit association of professionals, volunteers and supporters. The association provides networking and professional development opportunities for its members, and supports public policies that promote quality job creation and sustainable economic development throughout the state. For more information, visit www.geda.org

 

About AKESOgen, Inc.

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping

Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping

http://www.prweb.com/releases/2017/09/prweb14726130.htm

In this webinar, which LabRoots will host October 25, attendees will gain a better understanding of how the recently developed Axiom Precision Medicine Research Array can be used in a wide variety of disease and therapeutic research areas.

Yorba Linda, Ca (PRWEB) September 27, 2017 — As more is discovered about the implications of genetic variation in 21st century medicine, the utilization of genotyping as a molecular tool both in the research and clinical setting is as important and popular as ever. This presentation will exemplify the power and precision of the Applied BiosystemsTM AxiomTM Genotyping Platform in several settings.

In this webinar, which is sponsored by Thermo Fisher Scientific, participants will learn of the flexibility and accuracy of the Axiom Genotyping platform through comprehensive demonstration, as well as how it can be used to power large-scale genomic studies. They will learn about and discuss the Applied BiosystemsTM PharmacoScan Solution for pharmacogenomics research and its usefulness in clinical research trials for stratifying populations.

Examples will include the use of Applied BiosystemsTM AxiomTM Genotyping Arrays in the Department of Veterans Affairs’ Million Veteran Program (MVP), the use of the Applied BiosystemsTM AxiomTM Precision Medicine Research Array, the use of the PharmacoScan Solution for pharmacogenetics, as well as using a unique custom array for potential dementia risk assessment.

Dr. Mark Bouzyk, co-founder and CSO of AKESOgen, Inc., will be the speaker for this event.

Bouzyk currently serves as co-founder and chief scientific officer of AKESOgen, Inc., a genomics, pharmacogenomics and biobanking company. Prior to AKESOgen, he spent five years as a faculty member in the Department of Human Genetics at Emory University. Bouzyk earned his doctorate degree in human molecular genetics from the University of Hertfordshire; his interests lie in Pharmacogenetics as well as candidate gene and genomic association studies to identify genes for both common and rare diseases.

For Research Use Only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

About LabRoots

LabRootsis the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
AKESOgen

For the Third Year in a Row AKESOgen makes Annual List of America’s Fastest-Growing Private Companies—the Inc.500

AKESOgen Ranks as the No. 33 Healthcare Company and 448th Overall on the 2017 Inc.500

NEW YORK and ATLANTA August 16, 2017Inc. magazine today ranked AKESOgen, 33rd as a Healthcare company and 448th overall on its 36th annual Inc. 500, the most prestigious ranking of the nation’s fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment— its independent small businesses. Companies such as Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, and many other well-known names gained their first national exposure as honorees of the Inc. 500|5000.

 

“For the third consecutive year, we are delighted to be recognized as an Inc.500 honoree, sharing a pedigree with Intuit, Zappos, Under Armour, GoPro, Timberland, Clif Bar, Patagonia, Oracle, Box, Grubhub, and dozens of other Inc.500 alumni that have gone on to be household names.” commented AKESOgen CEO Robert Boisjoli.

 

“Understanding your own genetic make up and what your DNA says about you is becoming more and more a part of our everyday lives and will only continue to increase – especially with new technologies which make this information more and more accessible to the public. We are fortunate to be front and center in this new wave of emerging precision medicine molecular capabilities which are rapidly becoming mainstrain in our society.” says Mark Bouzyk, PhD, AKESOgen’s Chief Scientific Officer.

 

The 2017 Inc. 5000, unveiled online at Inc.com and with the top 500 companies featured in the September issue of Inc. is the most competitive crop in the list’s history. The average company on the list achieved a mind-boggling three-year average growth of 481%. The Inc. 5000’s aggregate revenue is $206 billion, and the companies on the list collectively generated 619,500 jobs over the past three years. Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000.

 

“The Inc. 5000 is the most persuasive evidence I know that the American Dream is still alive,” says Inc. President and Editor-In-Chief Eric Schurenberg. “The founders and CEOs of the Inc. 5000 tell us they think determination, risk taking, and vision were the keys to their success, and I believe them.”

 

About Inc. Media:

Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today’s innovative company builders. Winner of the National Magazine Award for General Excellence in both 2014 and 2012. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 18,000,000 today.  For more information, visit www.inc.com.

 

For more information contact:

Inc. Media

Drew Kerr

212-849-8250

drew@four-corners.com

 

About AKESOgen, Inc.

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and College of American Pathology (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

 

Media Contact:

Marissa Cooke, Director, Business Development and Marketing, AKESOgen, Inc. +1 770-542-0890, or mcooke@akesogen.com

 

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail